Paratek Pharmaceuticals, Inc. (PRTK) Research

Paratek Pharmaceuticals, Inc., a biopharmaceutical firm headquartered in Boston, Massachusetts, and founded in 1996, is actively engaged in the commercialization of its products. The company's core mission involves the creation and market introduction of crucial medical treatments for severe illnesses or major public health crises, intended for civilian, governmental, and military applications. Their flagship therapeutic offerings include NUZYRA and SEYSARA. NUZYRA is a comprehensive, once-daily antibiotic, available in both oral and intravenous forms, prescribed for adult patients battling community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens. SEYSARA, a medication derived from the tetracycline class, is specifically formulated to address moderate to severe cases of acne vulgaris. Beyond its internal development, Paratek maintains several strategic alliances. This includes licensing and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc. The company also holds a license from Tufts University, enabling the development and commercialization of solutions for bacterial or microbial diseases. Furthermore, a significant contract with the Biomedical Advanced Research and Development Authority (BARDA) is in place to advance NUZYRA for treating pulmonary anthrax. Additionally, Paratek has a licensing agreement with Tetraphase Pharmaceuticals, Inc. to oversee the development, import, and sale of the XERAVATM product, utilized for complicated intra-abdominal infections of bacterial origin.

Market snapshot

Symbol
PRTK
Price
$2.23
Day change
+1.83%
Market cap
$127.8M
P/E ratio
-1.91x
52-week range
1.29-3.65
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • aTyr Pharma, Inc. (ATYR)
  • Decibel Therapeutics, Inc. (DBTX)
  • Graybug Vision, Inc. (GRAY)
  • Kinnate Biopharma Inc. (KNTE)
  • NGM Biopharmaceuticals, Inc. (NGM)
  • Pardes Biosciences, Inc. (PRDS)
  • Quoin Pharmaceuticals, Ltd. (QNRX)
  • Selecta Biosciences, Inc. (SELB)

Recent insider activity

  • Baylor-Henry Minnie — D-Return (32800 shares) on 2023-09-21
  • Baylor-Henry Minnie — D-Return (26400 shares) on 2023-09-21
  • Baylor-Henry Minnie — D-Return (12800 shares) on 2023-09-21
  • Hoffmann Rolf K — D-Return (64000 shares) on 2023-09-21
  • Hoffmann Rolf K — D-Return (7000 shares) on 2023-09-21

Open Paratek Pharmaceuticals, Inc. (PRTK) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.